Projects per year
Fingerprint
Dive into the research topics where Matthew Philip Goetz is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 9 Finished
-
3 Things You Should Know About TROP2 as a Therapeutic Target in Triple-Negative Breast Cancer
O’Shaughnessy, J., Goetz, M. P. & Rugo, H. S., Jan 12 2026, In: Oncology (United States). 39, 8, p. 368-371 4 p.Research output: Contribution to journal › Article › peer-review
-
Adjuvant endocrine therapy omission in ER-positive breast cancer treated with neoadjuvant chemotherapy.
Choong, G. M. Y., Hoskin, T. L., Olson, C., Ingle, J. N., Boughey, J. C. & Goetz, M. P., Jun 2026, In: Journal of Clinical Oncology. 44, p. 525 1 p.Research output: Contribution to journal › Article › peer-review
-
Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial
Kong, T., Mabry, A., Highkin, M., Wang, A. Z., Hoog, J., Guo, Z., Gonzales-Gonzales, A., Thomas, S., Song, Y., Gao, F., Opyrchal, M., Peterson, L., Ademuyiwa, F., Margenthaler, J., Aft, R., Glover-Collins, K., Nehring, L., Tao, Y., Sanati, S. & Hagemann, I. S. & 14 others, , Dec 2026, In: Nature communications. 17, 1, 949.Research output: Contribution to journal › Article › peer-review
Open Access -
Comparative effectiveness of adjuvant chemotherapy on survival in node-positive (N2/N3), stage III ER+/HER2− invasive lobular breast cancer (ILC) versus invasive ductal cancer (IDC).
Yadav, S. K., Hoskin, T. L., Boughey, J. C., Goetz, M. P. & Giridhar, K., Jun 2026, In: Journal of Clinical Oncology. 44, p. 545 1 p.Research output: Contribution to journal › Article › peer-review
-
Effects of ovarian ablation or suppression on breast cancer recurrence and survival: patient-level meta-analysis of 15 000 women in 23 randomised trials
[email protected] Breast Cancer Trialists' Collaborative Group (EBCTCG), May 2 2026, In: The Lancet. 407, 10540, p. 1699-1711 13 p.Research output: Contribution to journal › Article › peer-review
Open Access